796
Biagi, P.L.; Bordoni, A.; Lorenzini, A.; Horrobin, D.F.; Hrelia, S. Essential fatty acid metabolism in long term primary cultures of rat cardiomyocytes: a beneficial effect of n-6:n-3 fatty acids supplementation
Mech Aging Dev 1999; 107(2): 181-95. (Abstract)
797
Easton, T.; Puri, B.K.; Richardson, A.J.; Das, I.; Horrobin, D.F. Improvement in schizophrenic symptoms is reflected by increased fatty acid levels: a single case
Scizophr Res 1999; 36: 105.
798
Hornych, A.; Girault, F.; Oravec, S.; Forette, B.; Horrobin, D.F. Effect of gamma-linolenic acid on plasma and membrane lipids and renal prostaglandins in old subjects [letter]
Br J Clin Pharmacol 1999; 48(6): 869-70.
800
Horrobin, D.F. Non-financial conflicts of interest are more serious than financial conflicts [letter]
Br Med J 1999; 318(7181): 466. (Full text)
801
Horrobin, D.F. The membrane phospholipid hypothesis of schizophrenia and its relation to neurodevelopment (Abstract)
Curr Opin Psychiatry 1999; 12: 186.
802
Horrobin, D.F. Biochemical mechanisms of lithium action: focus on intracellular signalling
Curr Opin Psychiatry 1999; 12: 345.
803
Horrobin, D.F. Lithium, essential fatty acids (efas) and eicosanoids
In: Birch, N.J. (Ed.) Lithium: 50 years of psychopharmacology. Weidner Publishing, Connetticut. 1999: 154-67.
804
Horrobin, D.F. The effects of antipsychotic drugs on membrane phospholipids: a possible novel mechanism of action of clozapine
In: Peet, M.; Glen, I.; and Horrobin, D.F. (Eds.) Phospholipid spectrum disorder in Psychiatry, Marius Press, Carnforth. ISBN: 1-871622-10-7 1999: 113-20.
805
Horrobin, D.F. A possible role for phospholipases in autism and Asperger's syndrome
In: Peet, M.; Glen, I.; and Horrobin, D.F. (Eds.) Phospholipid spectrum disorder in Psychiatry, Marius Press, Carnforth. ISBN: 1-871622-10-7 1999: 271-4.
806
Horrobin, D.F. A speculative overview: the relationship between phospholipid spectrum disorder and human evolution
In: Peet, M.; Glen, I.; and Horrobin, D.F. (Eds.) Phospholipid spectrum disorder in Psychiatry, Marius Press, Carnforth. ISBN: 1-871622-10-7 1999: 299-318.
807
Horrobin, D.F. The phospholipid concept of psychiatric disorders and its relationship to the neurodevelopmental concept of schizophrenia
In: Peet, M.; Glen, I.; and Horrobin, D.F. (Eds.) Phospholipid spectrum disorder in Psychiatry, Marius Press, Carnforth. ISBN: 1-871622-10-7 1999: 3-22.
808
Horrobin, D.F. [Title not known]
In: Riemersma, R.; Armstrong, R.; Kelly, R.; Wilson, R. (Eds.) Essential fatty acids and eicosanoids. American Oil Chemists Society, Champaign, Illinois. 1999: 341-3.
809
Horrobin, D.F. Interactions between lipid metabolism and schizophrenia: the biochemical changes which may have made us human
Lipids 1999; 34 Supp: S255.
810
Horrobin, D.F. Nutritional supplementation in schizophrenia
Newsletter, The Schizophrenia Association of Great Britain 1999; 27: 12-6.
811
Horrobin, D.F. Integration of phospholipid theories of schizophrenia and bipolar disorder with the dopamine theory and other neurotransmitterbased concepts (Abstract)
Presented at: International Conference on Schizophrenia, Santa Fe, April 1999.
812
Horrobin, D.F. Coenzyme A-independent transacylase in depression (Abstract)
Presented at: XI World Congress of Psychiatry, Abstracts Vol. II 1999: 120.
813
Horrobin, D.F. Fatty acid coenzyme A ligases (FACL) in schizophrenia (Abstract)
Presented at: XI World Congress of Psychiatry, Abstracts Vol. II 1999: 154.
814
Horrobin, D.F. Lipid metabolism, human evolution and schizophrenia. [review]
Prostaglandins Leukot Essent Fatty Acids 1999; 60(5-6): 431-7. (Abstract)
815
Horrobin, D.F. Schizophrenia and human evolution
Scizophr Res 1999; 36: 91.
816
Horrobin, D.F. Advertising claims for The Lancet [letter]
The Lancet 1999; 353(9154): 758.
817
Horrobin, D.F. and Phospholipid metabolism and schizophrenia
Scizophr Res 1999; 36: 105.
818
Horrobin, D.F. and Bennett, C.N. The membrane phospholipid concept of schizophrenia
In: Gattaz, W.F.; Hafner, H. (Eds.) Search for the causes of schizophrenia Vol IV: Balance of the century. Springer-Verlag. 1999: 261-78.
819
Horrobin, D.F. and Bennett, C.N. Phospholipid metabolism
Neurodevelopmental Workshop, Inverness, 17 Spetember 1999. Report to the Scottish Office. 1999.
820
Horrobin, D.F. and Bennett, C.N. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism
Prostaglandins Leukot Essent Fatty Acids 1999; 60(3): 141-67. (Abstract)
821
Horrobin, D.F. and Bennett, C.N. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes.
Prostaglandins Leukot Essent Fatty Acids 1999; 60(4): 217-34. (Abstract)
822
Horrobin, D.F. and Bennett, C.N. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, aging and osteoporosis: possible candidate genes
Prostaglandins Leukot Essent Fatty Acids 1999; 60: 217-34.
823
Hrelia, S.; Pession, A.; Buda, R.; Lorenzini, A.; Horrobin, D.F.; Biagi, P.L.; Bordoni, A. Concentration- and time-dependent effects of gamma-linolenic acid supplementation to tumor cells in culture
Prostaglandins Leukot Essent Fatty Acids 1999; 60(4): 235-41. (Abstract)
824
Jiang, W.G.; Hiscox, S.; Horrobin, D.F.; Bryce, R.P.; Mansel, R.E. Essential fatty acids regulate the expression of tumour suppressor genes in cancer cells
In: Riemersma, R.; Armstrong, R.; Kelly, R.; Wilson, R. (Eds.) Essential fatty acids and eicosanoids. American Oil Chemists Society, Champaign, Illinois. 1999: 303-11.
825
Leng, G.C.; Taylor, G.S.; Lee, A.J.; Fowkes, F.G.; Horrobin, D.F. Essential fatty acids and cardiovascular disease: the Edinburgh Artery Study
Vasc Med 1999; 4(4): 219-26. (Abstract)
826
McGahon, B.M.; Martin, D.S.; Horrobin, D.F.; Lynch, M.A. Age-related changes in LTP and antioxidant defenses are reversed by an alpha-lipoic acid-enriched diet
Neurobiol Aging 1999; 20(6): 655-64. (Abstract)
827
McGahon, B.M.; Martin, D.S.; Horrobin, D.F.; Lynch, M.A. Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids
Neuroscience 1999; 94(1): 305-14. (Abstract)
828
McGahon, B.M.; Murray, C.A.; Horrobin, D.F.; Lynch, M.A. Age-related changes in oxidative mechanisms and LTP are reversed by dietary manipulation
Neurobiol Aging 1999; 20(6): 643-53. (Abstract)
829
Nilsson, A.; Horrobin, D.F.; Rosengren, A. Phospholipids and abnormal involuntary movements in the general male population
In: Peet, M.; Glen, I.; and Horrobin, D.F. (Eds.) Phospholipid spectrum disorder in Psychiatry, Marius Press, Carnforth. ISBN: 1-871622-10-7 1999: 279-84.
830
Peet, M.; Glen, I.; Horrobin, D.F. (eds.) Phospholipid spectrum disorder in psychiatry
Marius Press, Carnforth. 339pp 1999. (Abstract)
831
Puri, B.K.; Richardson, A.J.; Easton, T.; Saeed, N.; Oatridge, A.; Hajnal, J.V.; Horrobin, D.F.; Bydder, G.M. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid associated with changes in brain structure and cerebral phospholipid metabolism
Schizophrenia Res 1999; 36: 312.
832
Puri, B.K.; Richardson, A.J.; Horrobin, D.F.; Easton, T.; Saeed, N.; Oatridge, A.; Hajnal, J.V.; Bydder, G.M. Structural brain changes in a patient with schizophrenia on serially registered MRI following treatment with EPA
Proc Int Magn Reson Med 1999; 7: 921.
833
Yoshimoto Furuie, K.; Yoshimoto, K.; Tanaka, T.; Saima, S.; Kikuchi, Y.; Shay, J.; Horrobin, D.F. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients
Nephron 1999; 81(2): 151-9. (Abstract)